MedTrace Logo

Colon Neoadjuvant FOLFOXIRI Study

NCT01941641 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-11-17

No results posted yet for this study

Summary

Objective tumour response rate to FOLFOXIRI to pre-operative therapy.

Conditions

Interventions

DRUG

neoadjuvant FOLFOXIRI

DRUG

Capecitabine

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Brigette MA, MD, FRCP · Chinese University of Hong Kong

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-09
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01941641 on ClinicalTrials.gov